🚀 VC round data is live in beta, check it out!
Coya Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Coya Therapeutics and similar public comparables like TuHURA Biosciences, Vistin Pharma, Nykode Therapeutics, Vytrus Biotech and more.
Coya Therapeutics Overview
About Coya Therapeutics
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Founded
2020
HQ
Employees
8
Website
Sectors
Financials (LTM)
EV
$75M
Coya Therapeutics Financials
Coya Therapeutics reported last 12-month revenue of $7M.
In the same LTM period, Coya Therapeutics generated had net loss of ($24M).
Revenue (LTM)
Coya Therapeutics P&L
In the most recent fiscal year, Coya Therapeutics reported revenue of $4M and EBITDA of ($17M).
Coya Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $7M | XXX | $4M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($17M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (485%) | XXX | XXX | XXX |
| EBIT Margin | (371%) | XXX | (485%) | XXX | XXX | XXX |
| Net Profit | ($24M) | XXX | ($15M) | XXX | XXX | XXX |
| Net Margin | (353%) | XXX | (419%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Coya Therapeutics Stock Performance
Coya Therapeutics has current market cap of $103M, and enterprise value of $75M.
Market Cap Evolution
Coya Therapeutics' stock price is $4.93.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $75M | $103M | 0.0% | XXX | XXX | XXX | $-0.71 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCoya Therapeutics Valuation Multiples
Coya Therapeutics trades at 11.1x EV/Revenue multiple, and (4.4x) EV/EBITDA.
EV / Revenue (LTM)
Coya Therapeutics Financial Valuation Multiples
As of March 18, 2026, Coya Therapeutics has market cap of $103M and EV of $75M.
Equity research analysts estimate Coya Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Coya Therapeutics has a P/E ratio of (4.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $103M | XXX | $103M | XXX | XXX | XXX |
| EV (current) | $75M | XXX | $75M | XXX | XXX | XXX |
| EV/Revenue | 11.1x | XXX | 21.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.4x) | XXX | XXX | XXX |
| EV/EBIT | (3.0x) | XXX | (4.3x) | XXX | XXX | XXX |
| P/E | (4.3x) | XXX | (6.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Coya Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Coya Therapeutics Margins & Growth Rates
Coya Therapeutics' revenue in the last 12 month declined by (44%).
Coya Therapeutics' revenue per employee in the last FY averaged $0.8M.
Coya Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (44%) | XXX | 124% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (485%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 119% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 174% | XXX | 250% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 284% | XXX | 335% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 585% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Coya Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| TuHURA Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Vistin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nykode Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vytrus Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Recce Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Coya Therapeutics M&A Activity
Coya Therapeutics acquired XXX companies to date.
Last acquisition by Coya Therapeutics was on XXXXXXXX, XXXXX. Coya Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Coya Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCoya Therapeutics Investment Activity
Coya Therapeutics invested in XXX companies to date.
Coya Therapeutics made its latest investment on XXXXXXXX, XXXXX. Coya Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Coya Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Coya Therapeutics
| When was Coya Therapeutics founded? | Coya Therapeutics was founded in 2020. |
| Where is Coya Therapeutics headquartered? | Coya Therapeutics is headquartered in United States. |
| How many employees does Coya Therapeutics have? | As of today, Coya Therapeutics has over 8 employees. |
| Who is the CEO of Coya Therapeutics? | Coya Therapeutics' CEO is Arun Swaminathan. |
| Is Coya Therapeutics publicly listed? | Yes, Coya Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Coya Therapeutics? | Coya Therapeutics trades under COYA ticker. |
| When did Coya Therapeutics go public? | Coya Therapeutics went public in 2022. |
| Who are competitors of Coya Therapeutics? | Coya Therapeutics main competitors are TuHURA Biosciences, Vistin Pharma, Nykode Therapeutics, Vytrus Biotech. |
| What is the current market cap of Coya Therapeutics? | Coya Therapeutics' current market cap is $103M. |
| What is the current revenue of Coya Therapeutics? | Coya Therapeutics' last 12 months revenue is $7M. |
| What is the current revenue growth of Coya Therapeutics? | Coya Therapeutics revenue growth (NTM/LTM) is (44%). |
| What is the current EV/Revenue multiple of Coya Therapeutics? | Current revenue multiple of Coya Therapeutics is 11.1x. |
| Is Coya Therapeutics profitable? | No, Coya Therapeutics is not profitable. |
| What is the current net income of Coya Therapeutics? | Coya Therapeutics' last 12 months net income is ($24M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.